Every 10-Q that Minerva Neurosciences, Inc (NERV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NERV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NERV filings page.
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing CNS therapies, led by roluperidone for negative symptoms in schizophrenia. A new Phase 3 confirmatory C19 trial is underway, targeting 380 patients on 64 mg roluperidone versus placebo; the first patient was screened on March 31, 2026, with topline efficacy data expected in the second half of 2027.
For the quarter ended June 30, 2026, Minerva reported net income of $17.5 million, mainly from a $27.6 million non-cash gain on remeasuring its warrant liability, while operating expenses rose to $10.6 million. For the first six months of 2026, it recorded a net loss of $107.9 million, including an $81.8 million non-cash loss on the same liability, with research and development expenses of $12.4 million and general and administrative expenses of $14.9 million.
Cash, cash equivalents, marketable securities and restricted cash totaled $75.4 million as of June 30, 2026, which management believes will cover operating commitments for at least twelve months. Capital structure includes a $232.7 million warrant liability and a $60.0 million royalty obligation, contributing to a stockholders’ deficit of $213.3 million.
Minerva Neurosciences reported a Q1 2026 net loss of $125.4 million, much larger than the prior year mainly because of a non-cash $109.4 million increase in the fair value of its warrant liability and $8.7 million of stock-based compensation.
Operating costs rose as the company prepared its confirmatory Phase 3 C19 trial for roluperidone in schizophrenia, with research and development expenses of $5.3 million and general and administrative expenses of $11.4 million. On March 31, 2026, the first patient was screened in the C19 trial.
Minerva ended March 31, 2026 with $78.2 million in cash, cash equivalents, marketable securities and restricted cash and believes this will fund operations for at least 12 months from issuance of the financial statements. Non-GAAP adjusted net loss was $7.3 million, reflecting the exclusion of non-cash warrant and equity compensation charges.
Minerva Neurosciences (NERV) reported Q3 2025 results and detailed a major post‑quarter financing. The company posted a net loss of $2.74 million as operating expenses fell year over year, driven by lower research and development and general and administrative costs. Cash, cash equivalents and restricted cash were $12.4 million as of September 30, 2025.
After quarter‑end, Minerva closed a private placement of Series A preferred stock and warrants for up to $200 million in gross proceeds. This included $80 million upfront for 80,000 Series A preferred shares, up to an additional $80 million from cash exercise of Tranche A warrants, and up to $40 million from Tranche B warrants tied to a milestone. The preferred stock automatically converts at $2.11 per share after stockholder approval, subject to a 9.99% beneficial ownership cap.
Management expects these funds to support the confirmatory Phase 3 trial of roluperidone, resubmission of its NDA, and U.S. launch readiness if approved. The liability related to the 2021 royalty sale remains at $60 million. Shares outstanding were 6,993,406 as of October 31, 2025.